

Emtricitabine/Tenofovir disoproxil fumarate



Brand Name: Truvada

Drug Class: Nucleoside Reverse Transcriptase Inhibitors

Drug Description

Truvada is a fixed-dose tablet containing two synthetic nucleoside analogues: emtricitabine and tenofovir disoproxil fumarate (DF). Each tablet contains emtricitabine 200 mg and tenofovir DF 300 mg. [1]

HIV/AIDS-Related Uses

Truvada (emtricitabine/tenofovir DF) was approved by the FDA on August 2, 2004, for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.[2] [3]

The approval of Truvada is based on safety and efficacy data that exist for both components individually and on bioequivalence studies demonstrating similar pharmacokinetic parameters of the combination product and the individual products. Efficacy results from studies using the combination of tenofovir and lamivudine are being extrapolated to support the use of Truvada. Truvada should be considered as an alternative to tenofovir and lamivudine for treatment-naïve patients who might benefit from a once-a-day regimen.[4]

Pharmacology

Emtricitabine and tenofovir DF each inhibit viral reverse transcriptase (RT), an enzyme HIV requires in order to replicate, by incorporating into viral DNA and terminating the viral DNA chain. (For more information, see the individual drug records for emtricitabine and tenofovir DF.)[5]

Emtricitabine, a synthetic nucleoside analogue of cytidine, is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits the activity of HIV-1 RT by competing with the natural substrate deoxycytidine 5'-triphosphate and by incorporating into nascent viral DNA, which results in chain termination. Emtricitabine 5'-triphosphate is a weak inhibitor of mammalian DNA polymerases alpha, beta, and epsilon and of mitochondrial DNA polymerase gamma.

Tenofovir DF is an acyclic nucleoside phosphonate

diester analogue of adenosine monophosphate and requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate. Tenofovir diphosphate inhibits the activity of HIV-1 RT by competing with the natural substrate deoxyadenosine 5'-triphosphate and by incorporating into DNA, which results in chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases alpha and beta and of mitochondrial DNA polymerase gamma.[6]

Truvada may be administered with or without food. Administration of Truvada following a high-fat meal or a light meal delayed the time of tenofovir peak plasma concentrations (C_{max}) by approximately 0.75 hour. The mean increases in tenofovir area under the concentration-time curve (AUC) and C_{max} were approximately 35% and 15%, respectively, when administered with a high-fat or light meal, compared with administration in the fasted state. In previous safety and efficacy studies, tenofovir DF was administered under fed conditions. Emtricitabine AUC and C_{max} were unaffected when Truvada was administered with either a high-fat or a light meal.[7]

Emtricitabine is rapidly and extensively absorbed following oral administration, reaching C_{max} at 1 to 2 hours post-dose. In one clinical trial, the mean absolute bioavailability of emtricitabine was 93% following multiple doses of the drug. The mean steady state C_{max} was 1.8 mcg/ml and the AUC over a 24-hour dosing interval was 10.0 hr mcg/ml. The mean steady state plasma trough concentration 24 hours after an oral dose was 0.09 mcg/ml.[8]

In vitro binding of emtricitabine to plasma proteins is less than 4%, and protein binding is independent of drug concentration over a range of 0.02 to 200 mcg/ml. In vitro studies indicate that emtricitabine does not inhibit cytochrome P450 (CYP) enzymes. Following administration of ¹⁴C-emtricitabine, the drug was 86% recovered in urine and 14% in feces. Thirteen percent of urine-recovered drug were metabolites, including 3'-sulfoxide diastereomers and 2'-O-glucuronide; no other metabolites were

Emtricitabine/Tenofovir disoproxil fumarate



Pharmacology (cont.)

identified. The plasma half-life of emtricitabine is approximately 10 hours. Renal clearance of the drug exceeds estimated creatinine clearance, indicating elimination by glomerular filtration and active tubular secretion. In patients with renal impairment, C_{max} and AUC were increased.[9]

Oral bioavailability of tenofovir in fasted patients is approximately 25%. Administration of tenofovir with a high-fat meal increases the oral bioavailability, with an increase in tenofovir AUC of approximately 40% and an increase in C_{max} of approximately 14%. Food delays the time to tenofovir C_{max} by approximately 1 hour. Following oral administration of a single 300-mg dose of tenofovir to HIV infected patients in the fasted state, C_{max} is achieved in approximately 1 hour. C_{max} and AUC values are approximately 296 ng/ml and approximately 2,287 hr(ng)/ml, respectively. The pharmacokinetics of tenofovir are dose proportional over a wide dose range and are not affected by repeated dosing. In vitro binding of tenofovir to human plasma or serum proteins is less than 0.7% and 7.2%, respectively, over the tenofovir concentration range of 0.01 to 25 mcg/ml. Following intravenous (IV) administration of tenofovir in doses of 1.0 mg/kg and 3.0 mg/kg, the volume of distribution at steady-state approximates 1.3 l/kg and 1.2 l/kg, respectively.[10]

In vitro studies indicate that neither tenofovir DF nor tenofovir are substrates of CYP enzymes. Following IV administration of tenofovir, approximately 70% to 80% of the dose is recovered in the urine as unchanged drug within 72 hours of dosing. Following single-dose, oral administration, the terminal half-life is approximately 17 hours. After multiple oral doses of tenofovir DF under fed conditions, approximately 32% of the administered dose is recovered in urine over 24 hours. Tenofovir is eliminated by a combination of glomerular filtration and active tubular secretion. There may be competition for elimination with other compounds that are also renally eliminated.[11] Tenofovir is principally eliminated by the kidney. Dosing adjustment is recommended in all patients with creatinine clearance less than 50 ml/min. Dosage adjustments for renal impairment are available in the prescribing information. However, no safety

data are available in patients with renal dysfunction who received tenofovir using these guidelines.[12]

One Truvada tablet is bioequivalent to one emtricitabine tablet (200 mg) plus one tenofovir DF tablet (300 mg) following single-dose administration to healthy adults.[13]

HIV-1 isolates with reduced susceptibility to the combination of emtricitabine and tenofovir have been selected in vitro. Genotypic analysis of these isolates identified the M184I/V and K65R amino acid substitutions in viral RT.[14] Cross resistance among certain nucleoside reverse transcriptase inhibitors has been recognized. These in vitro substitutions are also observed in some HIV-1 isolates from patients failing treatment with tenofovir in combination with either lamivudine or emtricitabine and with either abacavir or didanosine. Therefore, cross resistance among these drugs may occur in patients whose virus harbors either or both of these amino acid substitutions.[15]

Adverse Events/Toxicity

Severe, acute exacerbations of hepatitis B virus (HBV) have been reported in patients who have discontinued emtricitabine or tenofovir DF. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue Truvada and are coinfecting with HBV and HIV. If appropriate, initiation of anti-HBV therapy may be warranted.[16]

Immune reconstitution syndrome has been reported in some patients treated with combination antiretroviral therapy, including Truvada. During the initial phase of combination antiretroviral therapy, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections (such as *Mycobacterium avium* infection, cytomegalovirus, *Pneumocystis jirovecii* pneumonia, or tuberculosis), which may necessitate further evaluation and treatment.[17]

Emtricitabine and tenofovir DF are principally eliminated in the kidney; therefore, dosing interval adjustments of Truvada are recommended for patients with decreased creatinine clearance.

Emtricitabine/Tenofovir disoproxil fumarate



Adverse Events/Toxicity (cont.)

Truvada should not be administered to patients with low creatinine clearance or to those who require hemodialysis.[18]

Drug and Food Interactions

The manufacturer recommends that Truvada not be used as a component of a triple-nucleoside regimen.[19] Use of Truvada should be avoided in patients who are concurrently using or have recently used a nephrotoxic agent. Patients at risk of, or with a history of, renal dysfunction and patients receiving concomitant nephrotoxic agents should be monitored for changes in serum creatinine and phosphorus.[20]

Contraindications

Truvada is contraindicated in patients with previously demonstrated hypersensitivity to any of the components of the product, including emtricitabine and tenofovir DF.[21]

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretroviral medications. A majority of these cases have been in women. Obesity and prolonged nucleoside exposure may be risk factors.[22] Truvada is not indicated for the treatment of chronic HBV infection, and the safety and efficacy of Truvada have not been established in patients coinfecting with HBV and HIV.[23]

Clinical Trials

For information on clinical trials that involve Emtricitabine/Tenofovir disoproxil fumarate, visit the ClinicalTrials.gov web site at <http://www.clinicaltrials.gov>. In the Search box, enter: Emtricitabine/Tenofovir disoproxil fumarate AND HIV Infections.

Dosing Information

Mode of Delivery: Oral.[24]

Dosage Form: Film-coated tablets containing

emtricitabine 200 mg and tenofovir DF 300 mg (equivalent to 245 mg of tenofovir disoproxil).[25]

The recommended dosage of Truvada for adults 18 years or older is one tablet once a day.[26]

Patients with lowered creatinine clearance (30 to 49 ml/min) should receive one tablet every 48 hours.[27]

Truvada should not be prescribed for patients requiring dosage adjustment, such as those with reduced renal function (creatinine clearance less than 30 ml/min or requiring hemodialysis).[28]

Storage: Store tablets at 25 C (77 F); excursions permitted between 15 C and 30 C (59 F and 86 F). Keep container tightly closed and dispense only in original container. Do not use if seal over bottle opening is broken or missing.[29]

Chemistry

CAS Name: Emtricitabine: 143491-57-0 / Tenofovir disoproxil fumarate: 202138-50-9[30]

CAS Number: Emtricitabine: (2R-cis)-4-Amino-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone / Tenofovir disoproxil fumarate: Bis(hydroxymethyl) [[[(R)-2(6-Amino-9H-purin-9-yl)-1-methylethoxy] methyl]phosphonate,bis(isopropyl carbonate) (ester), fumarate (1:1)[31]

Molecular formula: Emtricitabine: C8-H10-F-N3-O3-S / Tenofovir disoproxil fumarate: C19-H30-N5-O10-P.C4-H4-O4[32]

Emtricitabine: C38.86%, H4.08%, F7.68%, N17.00%, O19.41%, S12.97% / Tenofovir disoproxil fumarate: C43.47%, H5.39%, N11.02%, O35.25%, P4.87%[33]

Molecular weight: Emtricitabine: 247.24 / Tenofovir disoproxil fumarate: 635.52[34]

Melting point: Emtricitabine: 136 C to 140 C[35]

Physical Description: Emtricitabine: White to off-white crystalline powder.[36]

Emtricitabine/Tenofovir disoproxil fumarate



Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET

Chemistry (cont.)

Tenofovir DF: White to off-white crystalline powder.[37]

Solubility: Emtricitabine: 112 mg/ml in water at 25 C.[38]

Tenofovir DF: 13.4 mg/ml in water at 25 C.[39]

Further Reading

[No authors listed] Truvada trials hold promise for new HIV prevention strategy. Once-a-day might keep HIV away. *AIDS Alert*. 2006 May;21(5):49-52.

Gazzard BG. Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients. *Expert Opin Pharmacother*. 2006 Apr;7(6):793-802.

Muñoz de Benito RM, Arribas López JR. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. *Expert Rev Anti Infect Ther*. 2006 Aug;4(4):523-35.

Manufacturer Information

Emtricitabine/Tenofovir disoproxil fumarate
Gilead Sciences Inc
333 Lakeside Dr
Foster City, CA 94404
(800) 445-3235

Truvada
Gilead Sciences Inc
333 Lakeside Dr
Foster City, CA 94404
(800) 445-3235

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: http://aidsinfo.nih.gov/live_help

Emtricitabine/Tenofovir disoproxil fumarate



References

1. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 1. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
2. FDA - FDA Approves Two Fixed-Dose Combination Drug Products for the Treatment of HIV-1 Infection. Available at: <http://www.fda.gov/bbs/topics/news/2004/NEW01099.html>. Accessed 11/05/08.
3. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 12. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
4. Gilead Sciences - Truvada Prescribing Information, May 2008, pp. 13-4. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
5. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 29. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
6. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 21. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
7. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 15. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
8. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 14. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
9. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 14. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
10. FDA - Truvada Prescribing Information, 05/21/07, pp. 4-5. Available at: <http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011bl.pdf>. Accessed 11/05/08.
11. FDA - Truvada Prescribing Information, 05/21/07, p. 5. Available at: <http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011bl.pdf>. Accessed 11/05/08.
12. FDA - Truvada Prescribing Information, 05/21/07, p. 5. Available at: <http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011bl.pdf>. Accessed 11/05/08.
13. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 4. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
14. Gilead Sciences - Truvada Prescribing Information, May 2008, pp. 22-3. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
15. Gilead Sciences - Truvada Prescribing Information, May 2008, pp. 22-3. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
16. Gilead Sciences - Truvada Prescribing Information, May 2008, pp. 3-5. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
17. FDA - Truvada Prescribing Information, 05/21/08, p. 6. Available at: <http://www.fda.gov/cder/foi/label/2007/021356s021,021752s011bl.pdf>. Accessed 11/05/08.
18. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 6. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
19. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 3. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
20. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 1. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
21. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 4. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
22. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 4. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
23. Gilead Sciences - Truvada Prescribing Information, May 2008, pp. 4-5. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
24. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 26. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
25. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 26. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
26. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 1. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
27. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 1. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
28. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 16. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
29. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 17. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.

Emtricitabine/Tenofovir disoproxil fumarate



30. ChemIDplus - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp>. Accessed 11/05/08.
31. USPD - 2003; pp. 311, 833
32. ChemIDplus - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp>. Accessed 11/05/08.
33. Merck Index - 2006; p. 607 / Other source, calculation
34. USPD - 2003; pp. 311, 833
35. Merck Index - 2006; p. 607
36. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 13. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
37. Gilead Sciences - Truvada Prescribing Information, May 2008, pp. 13-4. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
38. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 13. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.
39. Gilead Sciences - Truvada Prescribing Information, May 2008, p. 14. Available at: http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 11/05/08.